Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Annals of Nutrition & Metabolism
|
June 15, 2017
Effects of Dehydration on Brain Functioning: A Life-Span Perspective
Nathalie Pross
British Journal of Clinical Pharmacology
|
March 19, 2015
Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers
Nathalie Pross, Alain Patat, Philippe Vivet, et al.
Plos One
|
April 15, 2014
Effects of changes in water intake on mood of high and low drinkers
Nathalie Pross, Agnès Demazières, Nicolas Girard, et al.
European Journal of Applied Physiology
|
April 23, 2013
Circadian variation and responsiveness of hydration biomarkers to changes in daily water intake
Erica Perrier, Agnès Demazières, Nicolas Girard, et al.
The British Journal of Nutrition
|
June 22, 2012
Influence of progressive fluid restriction on mood and physiological markers of dehydration in women
Nathalie Pross, Agnès Demazières, Nicolas Girard, et al.
Journal of Parkinson'S Disease
|
February 20, 2025
Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III
Dylan Trundell, Evan W Davies, Louise Barrett, et al.
NPJ Parkinson'S Disease
|
August 13, 2025
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials
Gennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
NPJ Parkinson'S Disease
|
July 2, 2025
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials
Gennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
Parkinsonism & Related Disorders
|
January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data
Tania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
Lancet (London, England)
|
May 28, 2026
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study
Tania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Annals of Nutrition & Metabolism
|
June 15, 2017
Effects of Dehydration on Brain Functioning: A Life-Span Perspective
Nathalie Pross
British Journal of Clinical Pharmacology
|
March 19, 2015
Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers
Nathalie Pross, Alain Patat, Philippe Vivet, et al.
Plos One
|
April 15, 2014
Effects of changes in water intake on mood of high and low drinkers
Nathalie Pross, Agnès Demazières, Nicolas Girard, et al.
European Journal of Applied Physiology
|
April 23, 2013
Circadian variation and responsiveness of hydration biomarkers to changes in daily water intake
Erica Perrier, Agnès Demazières, Nicolas Girard, et al.
The British Journal of Nutrition
|
June 22, 2012
Influence of progressive fluid restriction on mood and physiological markers of dehydration in women
Nathalie Pross, Agnès Demazières, Nicolas Girard, et al.
Journal of Parkinson'S Disease
|
February 20, 2025
Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III
Dylan Trundell, Evan W Davies, Louise Barrett, et al.
NPJ Parkinson'S Disease
|
August 13, 2025
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials
Gennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
NPJ Parkinson'S Disease
|
July 2, 2025
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials
Gennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
Parkinsonism & Related Disorders
|
January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data
Tania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
Lancet (London, England)
|
May 28, 2026
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study
Tania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, et al.
Page
of 2